+1.212.901.8009 sclassen@alzdiscovery.org

September 11-12, 2017 • Jersey City, NJ (across from NYC on the Hudson)
The purpose for this annual Alzheimer’s Drug Discovery Foundation (ADDF) conference is to accelerate the development of innovative treatments for Alzheimer’s disease, related dementias and cognitive aging.


The two-day meeting is organized around four sub-topics: Neuroinflammation; Neuroprotection and Neural Regeneration; Epigenetics and Cognitive Enhancing; and Misfolded Proteins and Proteostasis.

Attendees will see the diverse cutting-edge approaches ADDF scientists are undertaking and have opportunities for networking and partnership discussions with academic, industry, and foundation thought leaders.


This annual conference brings together leading researchers developing innovative treatments and cutting-edge diagnostic approaches for Alzheimer’s disease, related dementias and cognitive aging.

ADDF-funded investigators share findings on both novel and repurposed drug programs and biomarkers at various stages of the pipeline.

The two-day meeting is organized around four sub-topics:

I. Neuroinflammation;

II. Neuroprotection and Neural Regeneration;

III. Epigenetics and Cognitive Enhancing; and

IV. Misfolded Proteins and Proteostasis.

The conference offers a wide range of registration options (including early-bird rates) for researchers from the nonprofit, academic, biotech, and pharma sectors.


  • Highlight scientific progress on drug discovery programs aimed at treating Alzheimer’s disease and related dementias.
  • Increase networking opportunities for scientists to share information and resources.
  • Foster interdisciplinary and public-private partnerships and alliances.


The 2016 edition of this conference attracted close to 150 attendees from around the world.  Attendees included:

  • Academic and industry scientists engaged in drug discovery research for neurodegenerative diseases and CNS
  • Business development and licensing professionals
  • Alliance management professionals
  • Venture capitalists and other investors
  • Graduate students, PhD candidates and post-doctoral fellows.


The Alzheimer’s Drug Discovery Foundation invites applications for the 2017 ADDF Young Investigator Scholarships.  Ten scholarships will be presented.  These prestigious scholarships recognize early achievements and seek to encourage the career development of the next generation of research scientists. Submissions are due July 14thReview more at the Scholarship page.


The conference offers a variety of co-sponsorship and exhibition packages, customized to meet your company’s needs. Review the details on the Sponsorship and Exhibit pages and contact us today to secure your place at this year’s conference!

Session 1: Neuroinflammation

Neuroinflammation has long been recognized as a factor in Alzheimer’s patient brains. Historically, inflammation was thought to be a consequence of the disease process, but new research findings identifying inflammation related genes that increase one’s risk of developing Alzheimer’s have indicated inflammation as a fundamental trigger of disease progression and as a promising therapeutic strategy.

The talks in this session will highlight unique neuroinflammation targets and repurposing opportunities relevant to inflammation.

Session 2: Neuroprotection and Neural Regeneration

Alzheimer’s disease and related dementias are characterized by early loss of synapses and subsequent neurodegeneration. As such, a growing number of programs are developing drugs to enhance neuronal survival and regeneration and inhibit neuronal cell death mechanisms that are activated by injury or stress.

This session will feature therapeutic approaches that target neurotrophic factors or hormones that promote neuronal survival, strategies to convert neural stem cells into mature neurons, and approaches to prevent neuronal death.

Session 3: Epigenetics and Cognitive Enhancing

Epigenetic mechanisms may play a role in the onset and progression of Alzheimer’s disease and represent an emerging area for drug development. Currently available FDA-approved drugs for Alzheimer’s disease target the acetylcholinesterase or the NMDA receptor to improve cognitive function. However, many other cognitive-enhancing strategies are under investigation, including those that are approved for other indications.

The talks in this session will highlight advances in epigenetic therapeutics, comparative effectiveness research, and drug repurposing in treating or preventing cognitive symptoms associated with Alzheimer’s disease, mild cognitive impairment, and aging.

Session 4: Misfolded Proteins and Proteostasis

A shared feature of many chronic neurodegenerative diseases is the abnormal accumulation and/or aggregation of misfolded proteins, which often have deleterious neurotoxic and inflammatory consequences.  Due to this common mechanism, many research programs in the neurodegenerative disease space are exploring strategies to ameliorate the effects of toxic protein species.

Lectures in this session will cover drug discovery programs pursuing innovative routes towards solving the problem of misfolded proteins and protein accumulation, along with biomarker programs under development.

Important Deadlines



Scholarship application deadline for 2017 was July 14th. Read more


Discounted rooms are available at the hotel venue (Hyatt Regency Jersey City) until August 17th or earlier (if discounted room block sells out). Read more


Early bird registration was valid through August 11th.  Read more

Survey responses collected on the 2016 Meeting:

Overall quality of the 2016 meeting?

  • Excellent 75.0%
  • Very Good 25.0%
  • Poor 0%
  • Failed 0%

This was a very good opportunity to hear from drug developers in start-ups and academia.  This will be a source of new AD targets long before big pharma tackles them.  Liked the focus on drug discovery programs as opposed to basic research.

Attendee at the 2016 conference

It was very useful to see other early clinical programs.

Interesting biomarker session.

Excellent neuroinflammatory angle.

Good to know about HDAC-2 inhibitors.

Attendee at the 2015 Meeting

This remains a favorite meeting of mine due to the openness to new concepts and creative sharing of problem solving supportive and reinforcing rather than contentious-which given the breadth of viewpoints, is a welcome change.

Attendee at the 2014 Meeting

After my talk, three separate people approached me to set up collaborations on our common interests.

Now, that’s a successful meeting!

Speaker at the 2013 Meeting

Join us today!

Reserve a seat at the conference, consider sponsoring the event or exhibiting,
submit an application for scholarship or simply, spread the word about it!